Meeting
2017 ASCO Annual Meeting
Emergence of KRAS mutations and acquisition of resistance to EGFR blockade.
Authors
Takeshi Yamada
Department of Digestive Surgery, Nippon Medical School, Tokyo, Japan
Takeshi Yamada , Goro Takahashi , Takuma Iwai , Kohki Takeda , Kohji Ueda , Michihiro Koizumi , Seiichi Shinji , Yasuyuki Yokoyama , Keisuke Hara , Akihisa Matsuda , Satoshi Matsumoto , Keiichiro Ohta , Uchida Eiji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3598)
DOI
10.1200/JCO.2017.35.15_suppl.3598
Abstract #
3598
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant?
First Author: Lucie Karayan-Tapon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2020 ASCO Virtual Scientific Program
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
First Author: Christos Stelios Karapetis
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera